Finepoint Capital LP Grows Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Finepoint Capital LP boosted its position in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 57.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,111,104 shares of the company’s stock after purchasing an additional 403,700 shares during the quarter. EyePoint Pharmaceuticals makes up 0.5% of Finepoint Capital LP’s portfolio, making the stock its 17th biggest holding. Finepoint Capital LP owned 1.63% of EyePoint Pharmaceuticals worth $8,278,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. KLP Kapitalforvaltning AS acquired a new position in shares of EyePoint Pharmaceuticals during the 4th quarter worth approximately $59,000. AlphaQuest LLC increased its position in EyePoint Pharmaceuticals by 13,246.6% during the fourth quarter. AlphaQuest LLC now owns 9,743 shares of the company’s stock worth $73,000 after buying an additional 9,670 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of EyePoint Pharmaceuticals in the fourth quarter worth $76,000. China Universal Asset Management Co. Ltd. lifted its position in shares of EyePoint Pharmaceuticals by 40.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,472 shares of the company’s stock valued at $108,000 after acquiring an additional 4,179 shares in the last quarter. Finally, Teacher Retirement System of Texas boosted its stake in shares of EyePoint Pharmaceuticals by 22.4% during the fourth quarter. Teacher Retirement System of Texas now owns 15,192 shares of the company’s stock valued at $113,000 after acquiring an additional 2,782 shares during the last quarter. Institutional investors and hedge funds own 99.41% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. StockNews.com raised shares of EyePoint Pharmaceuticals to a “sell” rating in a research note on Friday, March 14th. Citigroup began coverage on EyePoint Pharmaceuticals in a research note on Tuesday, January 7th. They set a “buy” rating and a $33.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 price objective on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. Finally, Chardan Capital reiterated a “buy” rating and set a $33.00 target price on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. One equities research analyst has rated the stock with a sell rating and nine have issued a buy rating to the company. According to data from MarketBeat, EyePoint Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $26.63.

EyePoint Pharmaceuticals Price Performance

EYPT stock opened at $4.61 on Friday. The firm has a market cap of $316.84 million, a PE ratio of -2.31 and a beta of 1.41. The firm has a 50 day simple moving average of $6.47 and a 200 day simple moving average of $8.10. EyePoint Pharmaceuticals, Inc. has a 12 month low of $4.51 and a 12 month high of $23.65.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings data on Wednesday, March 5th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.10). EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. The firm had revenue of $11.60 million during the quarter, compared to analyst estimates of $11.02 million. As a group, sell-side analysts expect that EyePoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current year.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.